BRTXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
BioRestorative Therapies, Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026
$1.60+0.06 (+3.90%)
Close on Oct 19, 2026
- Market cap
- $28.36M
- P/E (TTM)
- –
- Dividend yield
- –
BioRestorative Therapies, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $300.00K | $300.00K | – | – | – | – | – | – | 83.4% | 0.0% |
| Royalty [Member] | $59.70K | $101.00K | $145.80K | – | – | – | – | – | 16.6% | -40.9% |
| Stem Pearls Skincare Products [Member] | – | – | – | $0 | $355 | $425 | $2.22K | $1.68K | – | – |
By region
From the segment and revenue-disaggregation notes of BioRestorative Therapies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.